Dr. Sarmad Sadeghi, MD, MS, PhD

Dr. Sadeghi practices at USC Norris Cancer Hospital in Los Angeles, California.

Dr. Sadeghi's NPI, 1316104797, was assigned on May 21, 2008. Dr. Sadeghi graduated from Tehran University of Medical Sciences School of Medicine in 1998. Dr. Sadeghi's California license number on file is A121663.

Dr. Sadeghi's primary practice is USC Norris Cancer Hospital, at 1441 Eastlake Ave, Los Angeles, CA.

Dr. Sadeghi's primary practice is USC Norris Cancer Hospital in Los Angeles, California. Dr. Sadeghi is also affiliated with Los Angeles General Medical Center. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Sadeghi to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sadeghi practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Sadeghi's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Sadeghi is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Sadeghi's licenses on file in 4 states: California, Arizona, Nevada and Ohio.

Dmand AI lists colorectal cancer, lung cancer and prostate cancer among the conditions Dr. Sadeghi treats.

CMS data shows 623 Medicare services from Dr. Sadeghi across 7 procedure codes in 2024, for 260 Medicare patients. Medicare paid $49,405 for them.

CMS counts 260 Medicare patients who saw Dr. Sadeghi in 2024. The largest group is 65 to 74, with 132 patients. 75% of them have cancer, and 75% have high blood pressure. 35% are also on Medicaid. Their average risk score is 2.50, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sadeghi's median patient age at 73, with 17% women.

In 2024, Dr. Sadeghi wrote 25 Medicare Part D claims. 92% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $191,485 in total drug cost. In 2021, CMS named 30 claims across 2 drugs.

Dr. Sadeghi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sadeghi as offering telehealth.

Dmand AI links 8 papers to Dr. Sadeghi, published from 2013 to 2025. 2013 was the busiest year, with 2. Dr. Sadeghi's most frequent co-authors are Afsaneh Barzi, MD, Hooman Djaladat, MD and Manju Aron, MD.

Dmand AI links Dr. Sadeghi to 3 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Carcinoma, Transitional Cell and Ureteral Neoplasms. University of Southern California sponsors the most, 2.

CMS Open Payments shows 34 general payments to Dr. Sadeghi from 9 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 67% of the total. Pfizer Inc. paid the most, $8,356.

Dr. Sadeghi graduated from Tehran University of Medical Sciences School of Medicine in 1998.

Dr. Sadeghi is in network with 11 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.